Abbreviations: AE, adverse event; AUC, area under the curve; CI, confidence interval; eGFR, estimated glomerular filtration rate; IQR, interquartile range; PK, pharmacokinetic. 
| INTRODUC TI ON
Tacrolimus, a calcineurin inhibitor, is a common maintenance immunosuppression drug used after solid organ transplantation. It has a narrow therapeutic index requiring frequent therapeutic drug monitoring to maintain concentrations within the therapeutic range.
Subtherapeutic concentrations in the early post-transplant period increase the risk of rejection, while concentrations above the target range contribute to drug-related toxicity. [1] [2] [3] [4] Tacrolimus is almost completely metabolized through the cytochrome P450 enzymes, CYP3A4 and CYP3A5, in the liver and to a lesser extent in enterocytes. 5 ABCB1 also contributes to tacrolimus metabolism to inactive metabolites but to a lesser extent. 6 Single nucleotide polymorphisms (SNPs) in the CYP3A5 gene significantly influence tacrolimus drug concentrations. [7] [8] [9] [10] Compared to nonexpressors (CYP3A5*3/*3), CYP3A5 expressors (CYP3A5*1/*1, *1/*3)
require twofold higher doses of tacrolimus to achieve target blood concentrations, 11 and show delayed achievement of target blood concentrations. CYP3A5*1/*1 genotype of donor has also been associated with higher tacrolimus dose requirements in liver transplant recipients. 12 However, a genome-wide association study at our center 13 and another study by Ghisal et al 14 did not identify association between CYP3A5 loci and biopsy-proven rejection.
Age is also an important determinant of tacrolimus clearance.
Plasma clearance of tacrolimus in children is higher (2-3 ml/kg/min) compared to adults (1-2 mL/kg/min) 15 due to proportionately larger liver size in children 16 and higher CYP3A4 activity during the first year of life. 10 Younger pediatric patients therefore need higher doses than adults to achieve similar tacrolimus trough concentrations. 17, 18 In our previous study of 37 heart transplant recipients, age and CYP3A5 genotype together accounted for 35% of the variability in tacrolimus dose requirements (P = 0.001) and 52% variability in the concentration/dose ratio (P < 0.001). 19 Zhao et al demonstrated that tacrolimus dose should be based on weight, hematocrit, and CYP3A5 genotype. 9 However, previous studies have not accounted for variability by age and have been limited to kidney transplant recipients, and therefore, it is unclear whether current genotype-guided dosing guidelines for tacrolimus apply to all ages and all organ transplants. 20 We hypothesized that age and genotype-guided starting dose will be associated with earlier and more stable therapeutic drug concentrations compared to standard dosing during 30 days after transplant.
| MATERIAL S AND ME THODS

| Study design
This was a single-center, randomized, semi-blinded pilot trial comparing CYP3A5 genotype-guided dosing to standard dosing for tacrolimus. Written informed consent was obtained from parents or legal guardians. Baseline demographics, medical history, and status at listing were collected prior to transplant. The study was reviewed and approved by the Institutional Research Ethics Board and Health Canada (ClinicalTrials.gov ID: NCT01655563). 
| Eligibility Criteria
| CYP3A5 genotyping
DNA was extracted from blood after enrollment, and genotyping for CYP3A5*3 (rs776746) was performed prior to tacrolimus initiation using a TaqMan assay (Applied Biosystems, Foster City, CA)
in the institutional-accredited clinical genetic testing laboratory. 
| Randomization
Participants were randomized after transplantation by the study coordinator in a 2:1 ratio to genotype-guided dosing vs standard dosing. This ratio was used to ensure that all genotypes were represented in the experimental arm as majority of patients (~70%) were expected to be nonexpressor (*3/*3 expressors ( Figure 1 ). Physicians or nurses caring for the patient, and participants were blinded to genotype and randomization arm but not to the starting dose. Participants were switched from study dosing to clinical dosing after the first 36-48 hours. The participants were followed after tacrolimus initiation for 30 ± 3 days.
| Study dosing
| Tacrolimus concentrations
The first steady-state trough concentration of tacrolimus (C0) in whole blood was measured at 36-48 hours (usually after 3-4 doses) after study drug initiation. Target therapeutic trough concentrations for the first 12 weeks post-transplant were 10-12 μg/L (heart and kidney) and this method of tacrolimus assay is 4-6%, and lower limit of detection is <1 μg/L. Tacrolimus dose and frequency, and tacrolimus 12 hours postdose trough concentrations were captured throughout hospital stay and on subsequent clinical outpatient visits.
| Tacrolimus pharmacokinetics
Steady-state tacrolimus pharmacokinetic (PK) profile was performed (generally between 5 and 12 days post-tacrolimus initiation). Whole blood samples were drawn from an indwelling peripheral or central venous catheter and were collected in EDTA tubes at C1, C2, C4, C6, C8, C10, and C12. For three young infants (≤6 months), an abbreviated PK profile was collected at C1, C2.5, C6, and C9. A 12-hour area under the curve (AUC) was calculated via trapezoidal rule.
| Clinical and laboratory data
Weight, blood pressure, concomitant medications, and creatinine levels were captured from medical records at baseline and study follow-up. At our center, heart transplant recipients receive rabbit Committee. All AEs were managed according to the standard clinical management practices and followed over a 30-day follow-up period.
| Adverse events (AEs) monitoring and reporting
| Study outcomes
The primary goal was to compare the efficacy of genotype-guided tacrolimus dosing during 30-day follow-up after transplant. The primary outcome (efficacy) was time to achieve therapeutic tacrolimus trough concentrations and to maintain stable therapeutic trough concentrations, which is defined as two consecutive concentrations at least 48 hours apart in the therapeutic range without any changes in tacrolimus dose. Additional efficacy outcomes included tacrolimus concentration/dose ratio, frequency of out-of-range concentrations (defined as concentrations greater than ±1 μg/L outside target therapeutic range for organ type), frequency of dose adjustments, and tacrolimus AUC. The secondary outcome (safety) was frequency of AEs between the two dosing arms during follow-up.
| Statistical analysis
Continuous variables were summarized as median (interquartile range), and categorical variables were reported as frequencies and
proportions. Medians were compared using Wilcoxon rank-sum test, and proportions were compared with Fisher's exact test. Time to first therapeutic concentration and time to stable trough concentrations were described using Kaplan-Meier survival. The log-rank test was used to assess across stratum differences. To account for repeated measurements within subjects, tacrolimus out-of-therapeutic range and dose adjustments were analyzed with repeated measures logistic regression models. Tacrolimus blood concentration and tacrolimus concentration/dose ratios were analyzed with mixed-effect models. AEs were analyzed using Poisson models adjusting for follow-up duration, genotype, and organ type. The occurrence of any kidney injury was assessed using a repeated measures generalized linear model adjusted for eGFR at tacrolimus initiation, time since tacrolimus initiation, genotype, and organ type. All models were adjusted for genotype and organ type. All statistical analyses were carried out using intention-to-treat method and performed using SAS v9.4 (SAS statistical software, Cary, NC).
| Study power
The enrollment target was 75 patients with the goal of randomizing 60 patients in a 2:1 ratio. Assuming a median time to first therapeutic concentration of 5 days, using a log-rank test, a sample size of 60 provides 80% power at alpha of 0.05 to detect a 2.5-day difference between the two dosing arms in the time to achieve first therapeutic concentration. expressors. Median (IQR) age at transplant was 2.1 (0.75-8.0) years, and 45% participants were male. Characteristics of participants by randomization arm are described in Table 1 . Figure 2a shows the time to achieve first tacrolimus blood concentration in the therapeutic range. Participants in the genotypeguided dosing arm achieved therapeutic range earlier than those in the standard clinical dosing arm (P = 0.049). The median (IQR) time to achieve first therapeutic concentration was 3.4 (2.5-6.6) days in the genotype-guided arm and 4.7 (3.5-8.6) days in the standard arm. 69% participants in the genotype-guided arm achieved stable therapeutic concentrations while only 44% in the standard arm achieved stable therapeutic concentrations within 30 days (P = 0.089). The median time to achieve stable therapeutic concentrations was 18 (14-27) days in those in the genotypeguided arm; however, in the standard dosing arm, median time could not be generated because <50% participants achieved stable therapeutic concentration during study follow-up. Figure 2B shows the difference in time to stable concentrations by dosing arm; the difference did not reach statistical significance (P = 0.13).
| RE SULTS
| Efficacy
Overall, 60% participants had at least one out-of-range tacrolimus concentration in the genotype-guided arm and 71% in the stan- 
| Safety
A total 192 AEs were reported during 30-day follow-up (Table 2) .
11% were possibly tacrolimus-related with no difference by dosing TA B L E 1 Characteristics of 53 trial participants by randomization arm arm. 4% were serious AEs; none were tacrolimus-related. There was no significant difference in the incidence of AEs between the study arms except for hematological AEs in which incidence was lower in genotype-guided dosing arm (0.41 [0.17, 0.99]). The most frequent early post-transplant complications included any kidney injury (66%), hypertension (49%), graft rejection (9%), hyperglycemia (6%), and seizures (4%) ( Table 2 ).
| D ISCUSS I ON
In this randomized pilot clinical trial comparing age and genotypeguided to standard tacrolimus starting dose in pediatric solid organ transplant recipients, we provide evidence that CYP3A5 genotypeguided dosing was safe and resulted in earlier attainment of target therapeutic concentrations with significantly fewer out-of-range concentrations than with standard dosing. In addition, 69% participants in the genotype-guided arm were able to maintain stable concentrations compared to only 44% in the standard arm during study follow-up, although this difference did not reach significance likely due to overall low proportion of participants (60%) meeting this end-point. While further studies are needed to include adjustments not only to starting dose but also to subsequent dose titrations to improve maintenance of stable therapeutic concentrations, the findings underscore the importance of stratifying genotypeguided dosing by age in a pediatric population. This is also the first trial that encompasses the three largest solid organ groups undergoing transplantation.
The findings in our study were consistent with findings by Thervet et al 22 that patients in genotype-guided dosing arm achieved first therapeutic target concentrations earlier than standard dosing arm. However, another randomized trial in adult kidney transplant recipients did not find any difference in proportion of patients achieving first steady-state therapeutic concentrations with CYP3A5 genotype-guided dosing. 23 Similar to other studies, 22, 23 this study showed no difference in the occurrence of AEs between the two arms during study follow-up although the definition of hypertension was different from current Hypertension Canada's 2017 guideline. 24 While the trial was not designed to study differences in clinical outcomes, prior studies in adults have reported high (15%-30%) intrapatient variability in tacrolimus trough concentrations 1, 25 with individuals with higher variability demonstrating higher risk of rejection and poor graft outcomes. [1] [2] [3] In another retrospective study, patients with subtherapeutic or supratherapeutic concentrations showed higher incidence of delayed graft function and longer hospital stay compared to those with therapeutic concentrations. 26 The ability to reduce the frequency of out-of-target concentrations through more precise individualized dosing therefore has a strong potential to improve clinical outcomes. The ability to reduce hospital length of stay and costs of frequent therapeutic drug monitoring in addition to reducing costs associated with complications could also result in substantial cost savings to the healthcare system. 27 Other factors can influence tacrolimus concentrations including organ type, liver function, hemoglobin levels, concomitant medications, feeding status, as well as donor genotype in liver transplants that can alter tacrolimus bioavailability or alter clearance through F I G U R E 2 (A) Time to achieve first tacrolimus blood concentration in the therapeutic range was lower with genotypeguided dosing (solid line, n = 35) compared to standard dosing (dash line, n = 18) (P = 0.049). (B) Time to achieve stable therapeutic tacrolimus blood concentrations (two consecutive concentrations at least 48 hours apart in the therapeutic range without change in tacrolimus dose) was not significantly different between dosing arms. Solid line, genotype-guided dosing arm (n = 35); dash line, standard dosing arm (n = 18) (P = 0.13) (A) Time to achieve first tacrolimus blood concentration in the therapeutic range (B) Time to achieve stable therapeutic tacrolimus trough concentrations the effect on CYP3A5 activity. 12, [28] [29] [30] However, the current trial was not designed or powered to study the confounding influence of donor genotype and other factors such as organ type and biochemical factors.
Although the trial planned to randomize 60 of the 75 patients enrolled, only 53 were randomized due to a higher than expected 
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